azd7789
mAbexperimentalBi-specific
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2021 (NCT04931654)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314771 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06681324 | Phase 2 | Dec 16, 2024 | AstraZeneca |
| NCT06432764 | Phase 1 | Aug 30, 2024 | AstraZeneca, Karolinska Institute |
| NCT06450197 | Phase 2 | Aug 28, 2024 | AstraZeneca |
| NCT06366451 | Early Phase 1 (Phase 1) | May 22, 2024 | AstraZeneca, Presage Biosciences |
| NCT06053424 | Phase 1 | Sep 25, 2023 | AstraZeneca, Karolinska Institute |
| NCT05702229 | Phase 2 | Jan 16, 2023 | AstraZeneca |
| NCT05452304 | Phase 1 | Jul 12, 2022 | AstraZeneca, Parexel |
| NCT05216835 | Phase 1/Phase 2 (Phase 2) | Mar 18, 2022 | AstraZeneca, Parexel |
| NCT04931654 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2021 | AstraZeneca |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 9 | 8 | 2 | 2021 |
| Karolinska Institute | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Parexel | For profit | 2 | 0 | 2 | 2022 |
| Presage Biosciences | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1